OBI Pharma Announces OBI-999 Presentation at 2020 World ADC Digital Meeting

Poster Presentations at AACR 2020 Virtual Annual Meeting II
June 22, 2020
Company Announcement on Board Resolutions
September 28, 2020

Presentation to highlight the scientific characteristics of the novel first-in-class anti Globo H antibody-drug conjugate (ADC), OBI-999.

TAIPEI, Taiwan, Sept 14, 2020/PRNewswire/OBI Pharma, Inc. (TPEx: 4174), a leader in Glycosphingolipid Immuno-Oncology therapeutics targeting the Globo Series antigens (Globo H and SSEA-4) and chemotherapeutics targeting AKR1C3, today announced a scientific presentation will be held for OBI-999 (anti-Globo H targeted ADC) at the World ADC Digital Scientific meeting on Sept 16, 2020.
The scientific presentation titled, “A Novel Globo H-targeting Antibody-drug Conjugate: OBI 999” with a follow-up live discussion and question session will be led by Ming-Tain Lai, PhD. Chief Scientific Officer at OBI Pharma. The presentation will highlight the results from pre-clinical studies of OBI Pharma’s first-in-class anti-Globo H antibody drug conjugate (OBI-999), including animal efficacy and safety data, supporting the ongoing Phase 1/2 human study ongoing at the MD Anderson Cancer Center in Houston, TX (USA).
“OBI Pharma is proud to present at the prestigious 2020 World ADC Digital conference for OBI-999, our novel anti-Globo H first-in-class ADC cancer therapeutic. We look forward to providing future updates of our ongoing clinical studies, which could provide an important cancer ADC therapeutic option to patients suffering from cancer worldwide,” stated Ming-Tain Lai, PhD.

Title: A Novel Globo H-targeting Antibody-drug Conjugate: OBI-999
Presenter: Ming-Tain Lai, PhD. Chief Scientific Officer at OBI Pharma, Inc. Taipei, Taiwan.
Presentation Date and Time: Wednesday, Sept. 16, 2020. 11:30 a.m. – 11:50 a.m. Eastern Time
Live Discussion & Question Session: Wednesday, Sept. 16, 2020. 12:30 p.m. Eastern Time